Influence of CGPR-receptor antagonists on regenerative processes in hepatopathies of toxic genesis

This article describes the results of an experiment on potentiation of the hepatoprotective agent "Hepaton" with a drugantagonist of CGPR receptors.
Calcitonin Gene Linked Peptide (CGRP) is a highly efficient vasoactive peptide released from sensory nerves, the main, most active form of which (α-form) is produced by alternative splicing. The CGRP receptor is a complex of a calcitonin-like receptor (CLR) and one transmembrane protein, RAMP1.
At the moment, one of the most urgent topics is the study of the role of this peptide in various pathogenetic processes in humans and animals. Due to the fact that the liver is one of the largest reservoirs for CGRP receptors, the role of this peptide in the regulation of liver pathologies is obvious. Thus, it has been reliably established that in hepatopathies of various origins, the concentration of CGRP in the blood plasma increases significantly, which determines the hyperkinetics of the portal circulation characteristic of liver lesions.
To assess the prospects of potentiation of hepatobiliary protector drugs using CGPR receptor antagonists, we used a drug with hepatoprotective activity "Hepaton" (developed by FGBOU VO "SPbGUVM", therapeutic dosage for rats - 0.5 mg / kg, duration of pharmacological correction - 7 days) in combination with monoclonal antibodies of class G2 (IgG2), binding with high affinity to the receptor of calcitonin-gene-related peptide (erenumab, Irinex, dosage for rats - 0.75 ml / kg, was used once before the start of the experiment) and their effect on the regeneration of hepatic pathology induced by the use of 1,2-dichloroethane (within 7 days) in standard dosages.
Based on both experimental and scientific literature data, it can be concluded that drugs antagonists of CGPR receptors have an extremely wide range of applications in the future, including for potentiating other drugs used for pharmacological correction of various pathologies.
Rational influence on CGPR receptors can reliably influence the maintenance of homeostasis and nociception of the hepatobiliary system.

1. Венгеровский А.И., Маркова И.В., Саратиков А.С. Доклиническое изучение гепатозащитных средств// Ведомости Фармакологического комитета. -1999. -№ 2. -С. 9-12.

2. Патент № 2672056 C2 Российская Федерация, МПК C07D 471/20, C07D 213/61, C07D 213/62. Способ получения антагонистов рецепторов CGRP: № 2014141158: заявл. 13.03.2013: опубл. 09.11.2018 / К. М. Белык, Э. Клитор, Ш. Ч. Ко [и др.]; заявитель МЕРК ШАРП И ДОУМ КОРП.

3. Патент № 2742414 C1 Российская Федерация, МПК A61K 31/198, A61K 31/355, A61K 31/575. Препарат комплексный с гепатопротекторной активностью для крупного рогатого скота: № 2020120624: заявл. 16.06.2020: опубл. 05.02.2021 / В. С. Понамарев, Н. Л. Андреева, О. С. Попова, В. А. Барышев.

4. Патент № 2742826 C2 Российская Федерация, МПК C07K 14/585, A61K 38/22, A61P 25/06. Пептидные антагонисты пептидных гормонов из семейства кальцитонина (CGRP) и их применение: № 2017119773: заявл. 06.06.2017: опубл. 11.02.2021 / К. Д. Соарес ; заявитель СОАРЕС Кристофер Дж.

5. Толочко, З. С. Влияние холецистокинина-8 (CCK-8) на артериальное давление и содержание кальцитонин-ген-связанного пептида (CGRP) в крови крыс при гипертензии, вызванной фруктозой или блокадой синтеза оксида азота / З. С. Толочко, В. К. Спиридонов // Бюллетень экспериментальной биологии и медицины. – 2021. – Т. 171. – № 5. – С. 608-612. – DOI 10.47056/0365-9615-2021-171-5-608-612.

6. CGRP signalling inhibits NO production through pannexin-1 channel activation in endothelial cells / P. S. Gaete, M. A. Lillo, M. Puebla [et al.] // Scientific Reports. – 2019. – Vol. 9. – No 1. – P. 7932. – DOI 10.1038/s41598-019-44333-w.

7. Dietary capsaicin normalizes CGRP peptidergic DRG neurons in experimental diabetic peripheral neuropathy / X. Y. Zhang, Z. Guo, T. P. Li, T. Sun // Scientific Reports. – 2021. – Vol. 11. – No 1. – P. 1704. – DOI 10.1038/s41598-021-81427-w.

8. Structure and dynamics of the CGRP receptor in apo and peptide-bound forms / T. M. Josephs, M. J. Belousoff, Y. L. Liang [et al.] // Science. – 2021. – Vol. 372. – No 6538. – P. eabf7258. – DOI 10.1126/science.abf7258originally.

9. TLR4 signaling selectively and directly promotes CGRP release from Vagal afferents in the mouse / L. Jia, S. Lee, J. K. Elmquist [et al.] // eNeuro. – 2021. – Vol. 8. – No 1. – P. 1-16. – DOI 10.1523/ENEURO.0254-20.2020.

10. Wallace MC, Hamesch K, Lunova M, Kim Y, Weiskirchen R, Strnad P, et al. Standard operating procedures in experimental liver research: thioacetamide model in mice and rats. Laboratory Animals. 2015; 49 (S1): 21–9

11. Руководство по содержанию и использованию лабораторных животных: Восьмое издание / Д. С. Гарбер, Р. В. Барби, Д. T. Билицки [и др.] ; Под редакцией И.В. Белозерцевой, Д.В. Блинова, М.С. Красильщиковой. – Восьмое издание. – Москва: Общество с ограниченной ответственностью "ИРБИС", 2017. – 304 с. – ISBN 978-5-9909917-0-5.